{"filing":{"accession_number":"0001193125-26-239362","cik":"0002096997","ticker":"KLRA","company_name":"Kailera Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"ck0002096997-20260526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-20260526.htm"},"events":[{"id":9037,"run_id":7933,"accession_number":"0001193125-26-239362","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"The filing discloses quarterly financial results for the period ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information about the registrant.","company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1520,"accession_number":"0001193125-26-239362","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses quarterly financial results for the period ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information about the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:20.788110+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1520,"accession_number":"0001193125-26-239362","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses quarterly financial results for the period ended March 31, 2026, via a press release furnished as Exhibit 99.1. This is a standard earnings release disclosure under Item 2.02, which is material to investors as it provides periodic financial performance information about the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:20.788110+00:00","company_name":"Kailera Therapeutics, Inc.","ticker":"KLRA","filing_date":"2026-05-26"}]}